VECTUS BIOSYSTEMS LIMITED — Investor Presentation 2026

May 14, 2026

ASX: VBS

ECTUS

BIOSYSTEMS

A differentiated approach to pulmonary fibrosis

Phase 1A

Safety Completed

Phase 1B

Next Value Inflection

IPF

Lead Indication

Tara Speranza | CEO & CTO

tsperanza@vectusbiosystems.com.au | vectusbiosystems.com.au

---

ECTUS

BIOSYSTEMS

ASX: VBS

Forward-looking statements:

This Vectus Biosystems Limited (Vectus or the Company or ASX:VBS) presentation contains forward looking statements that involve risks and uncertainties. It has been prepared for informational purposes only. It does not constitute an offer or invitation to subscribe for, purchase or otherwise deal in securities. Recipients should conduct their own due diligence. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable at this time, Vectus can give no assurance that these expectations will prove to be correct. Actual results could differ materially from those anticipated. Reasons may include risks associated with drug development and manufacture, risks inherent in the regulatory processes, delays in clinical trials, risks associated with patent protection, future capital needs or other general risks or factors.

The purpose of this presentation is to provide general information about Vectus and its subsidiary and business. The information in this presentation is current as at 13 May 2026. It is in summary form and is not necessarily complete. It should be read together with the Appendix 4D and Half-year report and other ASX announcements by VBS.

---

CAPITAL STRUCTURE | ASX: VBS As at 12 May 2026

VECTUS BIOSYSTEMS

SHARE PRICE

$0.125

per share (AUD)

MARKET CAPITALISATION

$6.69M

AUD

CAPITAL STRUCTURE

Shares on issue	53.54M
Share price	A$0.125
Market capitalisation	A$6.69M
Options	1.35M

---

THE PROBLEM

ECTUS BIOSYSTEMS

Idiopathic Pulmonary Fibrosis (IPF): A mostly fatal disease with no cure

Current therapies slow progression, none known to reverse fibrosis. Median survival: 2–5 years from diagnosis.

Significant orphan opportunity

IPF FACTS

• Incidence is rising; more common in men over 60
• Diagnosis often delayed 1–2 years after symptom onset
• Progressive, irreversible lung scarring (alveoli replaced by scar)
• Pirfenidone & nintedanib: ~50% slower decline; high discontinuation due to tolerability
• No approved therapy reverses established fibrosis
• Lung transplant is the only option for end-stage disease

---

ORPHAN DRUG DESIGNATION

VECTUS BIOSYSTEMS

IPF is a rare disease.

Vectus can target Orphan Drug Designation for VB0004 in IPF

IPF affects <200,000 Americans - meets FDA rare disease threshold

IPF as rare disease -precedent well established

Benefits begin at designation, which can occur at Phase 1 trial (not at approval)

Filing for ODD is a near-term, low-cost catalyst

---

MARKET OPPORTUNITY

ECTUS BIOSYSTEMS

A Platform Opportunity Across Fibrotic Disease

Fibrosis underlies >40% of deaths globally. Vectus' lead program targets IPF first - with platform expansion potential across heart, kidney, and liver.

Addressable Market by Indication (US$ Billions, 2030E)

IPF: Lead Indication

~3M patients globally. $5B+ market by 2030. No disease-reversing therapy approved. Rapid orphan drug pathway potential.

Cardiovascular Fibrosis

Heart failure largest US healthcare budget item. VB0004 shows reversal of cardiac fibrosis in preclinical models.

Chronic Kidney Disease

Dialysis & transplant costs $49B+ annually (US). Renal fibrosis reversal demonstrated at all doses in animal models.

Platform Value

One mechanism. Multiple organs. Early external validation: antifibrotic asset out-licensed to Canadian biotech.

---

OUR APPROACH

VECTUS
SWIMMING

VB0004: First-in-Class Antifibrotic with Human Safety Data

Differentiated Mechanism	Favourable Drug Profile	De-Risked Asset
• Targets VIP pathway via NPR-C receptor
• Increases nitric oxide & cGMP
• Downregulates TNF-α & pro-fibrotic mediators
• Dual: vasodilation + fibrolysis
• First-in-class VIP agonist platform	• Small molecule — oral, once-daily dosing
• Tmax 6–8 hrs; half-life ~10–15 hrs
• No accumulation over 14 days
• Stable >2 years - long shelf life
• GI tolerable unlike current options	• Phase 1 SAD & MAD completed
• No significant adverse events
• GMP manufacturing validated at 2 centres
• Composition-of-matter IP in major jurisdictions
• Preclinical reversal: lung, heart, kidney

---

THE DIFFERENTIATION

VECTUS BIOSYSTEMS

The only known antifibrotic to reverse established disease in preclinical models

VB0004 demonstrated reversal of established fibrosis in multiple preclinical organ models - a distinction no approved therapy has achieved.

	VB0004 (Vectus)	Nintedanib	Pirfenidone
Slows disease progression	✓	✓	✓
Reverses established fibrosis	✓ (preclinical)	X	X
Oral once-daily dosing	✓	X (2×/day)	X (3×/day)
Favourable tolerability	✓ (Phase 1)	Moderate	Moderate
Multi-organ activity	✓ Lung, Heart, Kidney	Lung only	Lung only
First-in-class mechanism	✓ NPR-C / VIP agonist	X	X

---

PULMONARY FIBROSIS DATA

VECTUS

VB0004 Reverses Established Lung Fibrosis in Preclinical Model

16-week Control
Established pulmonary fibrosis — collagen deposition throughout lung parenchyma

20-week Control (Vehicle)
Fibrosis has progressed — additional collagen deposition, reduced airspace

VB4-A79 (20 wks)
Significant reduction in fibrotic burden vs vehicle control — partial reversal

VB0004 (20 wks)
Marked reduction in fibrosis — near-normal lung architecture restored

Note: Bleomycin-induced pulmonary fibrosis model. VB0004 administered after fibrosis established (2 weeks post-bleomycin).

---

PULMONARY FIBROSIS DATA

VECTUS

VB0004 Reverses Established Lung Fibrosis in Preclinical Model

16-Week Fibrosis Model Control

Increased fibrosis (cyano), reduced capillaries

20-Week Fibrosis Model Control

Increasing fibrosis, decreasing capillaries

VB0004 in Fibrosis Model at 20 Weeks

Fibrosis removed, capillaries

Note: Bleomycin-induced pulmonary fibrosis model. VB0004 administered after fibrosis established (2 weeks post-bleomycin).

Histology: Masson's trichrome staining. Source: internal preclinical data.

---

PRECLINICAL EVIDENCE

ECTUS BIOSYSTEMS

Reversal of Established Fibrosis Across Multiple Organs

Published peer-reviewed data from European Journal of Pharmacology. Dose-dependent effects; normal tissue architecture restored.

---

PHASE 1 RESULTS

VECTUS

Phase 1a Completed: Strong Safety & Predictable Pharmacokinetics

SAD — Single Ascending Dose

Max planned: 300mg
Max tolerated: 300mg
No significant adverse events

Dose ceiling not reached

MAD — 14-Day Multiple Ascending Dose

Max planned: 100mg/day
Max tolerated: 100mg/day
No significant adverse events

Healthy subjects & mild hypertensives

6–8 hr

Tmax

~10–15 hr

Half-life

None

Accumulation over 14 days

Once daily

Consistent dosing profile

---

VECTUS BIOSYSTEMS

NEXT VALUE INFLECTION

Phase 1B: First Patient Data in Pulmonary Fibrosis

This is the milestone that de-risks the program, establishes antifibrotic activity in humans, and positions VBS for Phase 2 and strategic partnership discussions.

Population:	Mild pulmonary fibrosis / early ILD patients
Design:	Randomised, double-blind, placebo-controlled MAD
Duration:	21 days dosing — 2 doses, 2 groups
Primary Endpoint:	Safety, tolerability & dose-limiting toxicities
Biomarkers:	KL-6, SP-D, MMP-7, PRO-C3, FVC, DLCO
CRO:	CRO-led
Outcome:	Recommended Phase 2 dose + first antifibrotic signals in humans

---

CLINICAL ROADMAP

ECTUS

BIOSYSTEMS

Clear Path to Value Creation

Pipeline Overview

Program	Lead Indication	Stage	Status
VB0004	Pulmonary Fibrosis (IPF)
(Cardiovascular & Renal benefits also demonstrated)	Phase 1B Ready	Lead Program
VB4-A79	Pulmonary Fibrosis (non-scleroderma)	Preclinical	Pipeline
VB4-A32	Liver Fibrosis (NASH/ASH)	Preclinical	Pipeline
VB4-P5	Renal Fibrosis	Preclinical	Licensed — external validation

---

REGULATORY & COMMERCIAL STRATEGY

ECTUS

Partnering-Led Model with Regulatory Acceleration Pathways

REGULATORY PATHWAY

• Phase 1B → Phase 2 PoC

• Standard pathway; IPF patient population; biomarker-driven design

• Orphan Drug Designation

• IPF qualifies — accelerated review, exclusivity benefits, fee waivers

• FDA Engagement

• Type C / End-of-Phase 2 meetings planned to align on design and endpoints

• TGA / EMA Parallel

• Australian and European regulatory alignment from Phase 2 design

COMMERCIALISATION MODEL

Out-licensing led

Advance to Phase 1B/2 PoC, then regional or global licensing to established pharma

Platform value

Multiple antifibrotic assets create flexibility for parallel partnering by organ or geography

External validation

VB4-P5 already out-licensed to Canadian biotech — proof of platform interest

Payer readiness

PBS, Medicare, private insurers — fibrotic disease is a reimbursed category globally

Capital efficiency

CRO-led model; leverage partner infrastructure for Phase 3 and global launch

---

INTELLECTUAL PROPERTY & MANUFACTURING

ECTUS BIOSYSTEMS

Broad IP Protection + Validated GMP Manufacturing

PATENT PORTFOLIO

• VB0004 composition-of-matter: granted USA, Europe, Japan, China, Korea, Russia, Australia, Canada + others
• VB0004 library (~70 compounds): granted in all major jurisdictions
• VB4-A79 (pulmonary fibrosis): granted Australia, China; accepted USA, Europe
• VB4-A32 (liver fibrosis): granted US, Europe, Australia
• GMP synthesis method: granted USA, Australia, India
• >1,000 compound library encompassed within the patent estate

GMP MANUFACTURING

Two GMP centres validated
Process consistency confirmed

5kg scale demonstrated
Yield improves with scale; adequate for Phase 2 and beyond

Stability >2 years
Long shelf life — commercially viable; 3 validation batches underway

FDA Phase 1 & 2 ready
Manufacturing meets requirements for continued clinical development

---

LEADERSHIP & BOARD

VECTUS BIOSYSTEMS

Experienced Team Aligned to This Stage of Development

Dr Tara Speranza

CEO & CTO

20+ years across scientific research, commercial strategy & capital markets. Translational drug development at University of Sydney & University of Geneva. Led commercial partnership with Servier (Protelos). Extensive biotech investment and advisory roles.

Mr Maurie Stang

Non-Executive Deputy Chairman

30+ years in healthcare and biotechnology. Strong track record in global IP commercialisation. Executive Chairman of Lumitron Technologies.

Dr Ronald Shnier

Non-Executive Chairman

Radiologist; founder of one of Australia's first private MRI practices; former National Director of Diagnostic Imaging at Mayne Health; active in clinical research and international advisory boards. Dr Shnier was the Chief Medical Officer at I-MED Radiology Network for 7 years and continues to serve a Director on the Board of I-MED.

Ms Linda Walters

Non-Executive Director

25+ years in life sciences and healthcare. Deep familiarity with Vectus technology and IP. Expertise across commercialisation, finance, HR and IT.

---

MILESTONE STRATEGY

ECTUS

De-Risking Milestones

Stage 1

Phase 1B initiation & execution

• CRO engagement & Phase 1B trial costs
• Biomarker panel & PK/PD analysis
• Regulatory preparation (IND, FDA & TGA)
• Working capital — operations

Stage 2

Phase 2 PoC & partnering readiness

• Phase 2 trial design & initiation
• GMP manufacturing scale-up
• IP maintenance & new filings
• Strategic advisory & BD resourcing

KEY GATING EVENTS FOR SCALE CAPITAL

• Phase 1B safety & tolerability data in mild IPF patients

• Recommended Phase 2 dose established

• Antifibrotic biomarker signals (KL-6, MMP-7, PRO-C3)

• Regulatory alignment on Phase 2 design

---

WHY INVEST NOW

VECTUS BIOSYSTEMS

Vectus Biosystems — The Investment Thesis

| 01 | Unmet Need, Large Markets
IPF kills 2–5 years post-diagnosis. $5B+ global market. No approved therapy reverses fibrosis.
Vectus assets known to target substantial markets for cardiac, renal and hepatic diseases. |
| --- | --- |
| 02 | Differentiated & De-Risked
Phase 1 completed. Strong safety profile. Preclinical reversal of lung, heart, and kidney fibrosis. Published peer-reviewed data. |
| --- | --- |
| 03 | Clear Next Catalyst
Phase 1B in IPF patients is fully defined and ready. Biomarker-rich design maximises data value per dollar invested. |
| --- | --- |
| 04 | Broad IP & Platform

1,000 compounds. Patents granted in all major markets. External out-licensing validates platform interest. |
| --- | --- |
| 05 | Partnering-Optimised
Strategy built around early licensing to global pharma. CRO-led model is capital-efficient and transaction-ready. |
| --- | --- |
| 06 | Strategic Reset Complete
New CEO. Refined clinical plan. Renewed focus on IPF. Positioned for capital raise and Phase 1B initiation. |
| --- | --- |

---

ECTUS

BIOSYSTEMS

ASX: VBS

GET IN TOUCH

Dr Tara Speranza

CEO & CTO

Email: tsperanza@vectusbiosystems.com.au

Web: vectusbiosystems.com.au

ASX: VBS

---

VIP - TARGET VALIDATION - APPENDIX

VECTUS BIOSYSTEMS

Treatment with VIP reversed cardiac fibrosis in multiple animal models data from one was published in the paper entitled "Vasoactive intestinal peptide reverses existing myocardial fibrosis in the rat"

European Journal of Pharmacology 862 (2009) 172629

Common free available at bionosfibres

European Journal of Pharmacology

journal homepage: www.visonline.com/bioanalysis/phar

Full length article

Vasoactive intestinal peptide infusion reverses existing myocardial fibrosis in the rat

Karen A. Duggan*, George Hodge, Juchuan Chen, Tegan Hunter†

Vectus Biosystems, North Eylis, Australia

ARTICLE INFO

ABSTRACT

Ecospecific tissue failure

Vasoactive intestinal peptide

Ecosperine cardiac failure has become one of the major health challenges of the JEA century and now throughout our context in address this problem. The concentration of vasoactive intestinal peptide (VIP) in the heart has been shown to decrease as fibrosis (the pathology leading to heart failure) and occurred to become undetectable in and stage cardiomyopathy. We sought to determine whether replenishment of myocardial VIP might treat myocardial fibrosis and therefore represent a new therapeutic target.

Within Korea (site on a high 10.4%) cat, this were transformed to even time control, 4-week infusion of VIP (3-year-old, men) or vehicle control infusion. Myocardial VIP concentration was measured by radioimmunoassay, fibrosis was quantitated by computerised biohomoephrometry and changes in pre-fibrotic medsence were measured by quantitative mPCR.

Myocardial VIP increased significantly in VIP-treated cats compared with vehicle control controls (P < 0.05) while fibrosis in the VIP-treated rats was significantly lower than in both the tests (one control (P < 0.05) and

Treatment with VIP was also found to reverse interstitial fibrosis in the kidney in multiple animal models data from one was published in the paper entitled "Vasoactive intestinal peptide infusion reverses existing renal interstitial fibrosis via a blood pressure independent mechanism in the rat"

European Journal of Pharmacology 873 (2009) 173979

Cancers free available at bionosfibres

European Journal of Pharmacology

journal homepage: www.visonline.com/bioanalysis/phar

Full length article

Vasoactive intestinal peptide infusion reverses existing renal interstitial fibrosis via a blood pressure independent mechanism in the rat

Karen A. Duggan, George Hodge, Juchuan Chen, Sofie Trajanovska, Tegan Hunter†

Vectus Biosystems, North Eylis, Australia

ARTICLE INFO

ABSTRACT

Keywords

Mental illness

Tubulointerstitial fibrosis

Vasoactive intestinal peptide

Diabetes requiring renal failure is a minor epidemic. Despite an annual mortality of 24% for dialysis population has increased by 1.4% per annum. Regardless of the similar injury, tubulointerstitial fibrosis is a feature of the renal pathology and is inversely correlated with declining renal function. Current agents display little efficacy against tubulointerstitial fibrosis. Clearly, therapies effective against tubulointerstitial fibrosis and able to preserve kidney function are needed. Vasoactive intestinal peptide (VIP) has been shown to reverse pre-existing cardiac fibrosis. We sought to determine whether VIP is effective in tubulointerstitial fibrosis. Spontaneous hypertension (see 2009) on a 1.5% old diet were maintained in vitro three months; 4-week infusion of VIP (3-year-old, men) or vehicle control infusion. A fourth group, to match the blood pressure reduction achieved in the VIP infused group was included. Fibrosis was quantitated by computerised biohomoephrometry, changes in pre-fibrotic medsence were measured by quantitative mPCR and macrophage activation assessed by cyclic adheesion assay (Sorbitan × ADP) and one to six riboflavin with VIP. Tubulointerstitial fibrosis is the VIP variant.

VECTUS BIOSYSTEMS LIMITED